Free Trial
→ Are we ignoring the same signal Wall Street ignored in 1929? (From Weiss Ratings) (Ad)tc pixel Free ANIP Stock Alerts

ANI Pharmaceuticals (ANIP) Financials

ANI Pharmaceuticals logo
$78.51 -2.60 (-3.21%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$80.30 +1.79 (+2.28%)
As of 05/29/2026 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ANI Pharmaceuticals

Annual Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 15 3.93 -1.08 15 6.09 -23 -43 -50 17 -20 77
Consolidated Net Income / (Loss)		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Net Income / (Loss) Continuing Operations		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Total Pre-Tax Income 		22 8.68 16 20 3.16 -26 -56 -63 20 -22 96
Total Operating Income		 33 20 28 35 16 -16 -40 -35 47 0.58 111
Total Gross Profit		 64 80 98 129 143 121 116 178 305 364 542
Total Revenue		 76 129 177 202 207 208 216 316 487 614 883
Operating Revenue		 76 129 177 202 207 208 216 316 487 614 883
Total Cost of Revenue		 13 49 79 73 63 87 101 139 182 250 341
Operating Cost of Revenue		 13 49 79 73 63 87 101 139 182 250 341
Total Operating Expenses		 31 60 69 93 127 137 155 213 258 364 431
Selling, General & Admin Expense		 21 28 32 44 56 65 84 124 162 250 318
Research & Development Expense		 2.87 2.91 9.07 15 20 16 11 22 34 45 52
Depreciation Expense		 6.90 22 28 34 45 45 47 57 60 68 91
Impairment Charge		 0.00 6.69 0.90 0.00 0.08 0.45 2.37 - 0.00 7.60 0.77
Restructuring Charge		 - - - - - 0.00 0.00 5.68 1.13 0.00 0.00
Other Special Charges / (Income)		 - - - - 0.00 0.00 9.25 3.76 1.43 -5.97 -31
Total Other Income / (Expense), net		 -11 -11 -12 -15 -13 -9.95 -16 -27 -27 -23 -15
Interest Expense		 - - - - - - - 0.00 0.00 7.47 0.00
Interest & Investment Income		 -11 -11 -12 -15 -13 -9.45 -12 -28 -27 -18 -20
Other Income / (Expense), net		 0.04 -0.07 0.06 -0.55 -0.23 -0.49 -4.34 0.67 -0.16 2.27 4.76
Income Tax Expense		 6.36 4.74 17 4.56 -2.94 -3.41 -13 -15 1.09 -3.69 17
Preferred Stock Dividends Declared		 - - - - 0.00 0.00 0.19 1.63 1.63 1.63 1.16
Basic Earnings per Share		 $1.34 $0.34 ($0.09) $1.31 $0.51 ($1.88) ($3.40) ($3.05) $0.86 ($1.04) $3.50
Weighted Average Basic Shares Outstanding		 11.37M 11.45M 11.55M 11.68M 11.84M 11.96M 12.60M 16.26M 18.00M 19.32M 20.05M
Diluted Earnings per Share		 $1.32 $0.34 ($0.09) $1.30 $0.50 ($1.88) ($3.40) ($3.05) $0.85 ($1.04) $3.32
Weighted Average Diluted Shares Outstanding		 11.56M 11.57M 11.55M 11.77M 12.04M 11.96M 12.60M 16.26M 18.19M 19.32M 21.23M
Weighted Average Basic & Diluted Shares Outstanding		 11.50M 11.60M 12M 11.80M 12.11M 12.37M 17.27M 17.50M 21.08M 21.77M 22.42M

Quarterly Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 9.53 0.75 18 -2.69 -25 -11 15 8.14 26 27 29
Consolidated Net Income / (Loss)		 9.94 1.16 18 -2.29 -24 -10 16 8.55 27 27 29
Net Income / (Loss) Continuing Operations		 9.94 1.16 18 -2.29 -24 -10 16 8.55 27 27 29
Total Pre-Tax Income 		12 0.95 25 -2.29 -31 -14 20 11 34 31 40
Total Operating Income		 18 6.73 20 5.17 -21 -4.38 26 14 36 35 39
Total Gross Profit		 84 78 88 80 85 361 124 137 134 147 144
Total Revenue		 132 132 137 138 148 191 197 211 228 247 237
Operating Revenue		 132 132 137 138 148 191 197 211 228 247 237
Total Cost of Revenue		 48 53 49 58 63 -170 73 75 93 100 94
Operating Cost of Revenue		 48 53 49 58 63 - 73 75 93 100 94
Total Operating Expenses		 66 72 68 75 106 365 98 123 98 112 105
Selling, General & Admin Expense		 42 44 48 53 79 70 77 82 77 83 74
Research & Development Expense		 11 9.87 11 7.30 10 17 11 17 12 12 11
Depreciation Expense		 15 15 15 15 16 23 23 23 23 23 21
Other Special Charges / (Income)		 -2.56 1.99 -5.26 0.36 0.83 -1.89 -12 1.28 -14 -5.64 -0.18
Total Other Income / (Expense), net		 -6.44 -5.78 5.02 -7.46 -11 -9.38 -6.21 -3.37 -2.44 -3.29 1.33
Interest & Investment Income		 -6.40 -5.75 -4.60 -4.66 -2.33 0.29 -5.48 -5.44 -4.73 -4.41 -3.77
Other Income / (Expense), net		 -0.04 -0.03 9.62 -2.80 -1.18 -9.68 -0.72 2.07 2.29 1.12 5.10
Income Tax Expense		 1.57 -0.21 7.13 0.00 -7.33 -3.49 4.31 1.98 7.18 3.99 11
Preferred Stock Dividends Declared		 0.41 0.41 0.41 0.41 0.41 0.41 0.41 0.41 0.34 - 0.00
Basic Earnings per Share		 $0.46 $0.04 $0.84 ($0.14) ($1.27) ($0.47) $0.70 $0.37 $1.19 $1.24 $1.31
Weighted Average Basic Shares Outstanding		 18.88M 18.00M 19.10M 19.32M 19.40M 19.32M 19.61M 19.83M 20.07M 20.05M 20.91M
Diluted Earnings per Share		 $0.45 $0.05 $0.82 ($0.14) ($1.27) ($0.45) $0.69 $0.36 $1.13 $1.14 $1.28
Weighted Average Diluted Shares Outstanding		 19.13M 18.19M 19.42M 19.32M 19.40M 19.32M 20.05M 20.31M 21.09M 21.23M 21.54M
Weighted Average Basic & Diluted Shares Outstanding		 20.44M 21.08M 20.97M 21.04M 21.03M 21.77M 21.66M 21.70M 22.47M 22.42M 22.75M

Annual Cash Flow Statements for ANI Pharmaceuticals

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -14 -122 3.78 12 19 -54 92 -52 168 -76 141
Net Cash From Operating Activities		 17 27 39 67 46 15 3.32 -31 119 64 185
Net Cash From Continuing Operating Activities		 17 27 39 67 46 15 3.32 -31 119 64 185
Net Income / (Loss) Continuing Operations		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Consolidated Net Income / (Loss)		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Depreciation Expense		 6.90 22 28 34 45 45 47 60 60 68 91
Amortization Expense		 6.83 7.28 7.67 8.47 7.02 1.88 2.51 3.96 3.92 14 1.36
Non-Cash Adjustments To Reconcile Net Income		 7.43 19 12 11 13 26 16 23 21 49 42
Changes in Operating Assets and Liabilities, net		 -19 -25 -7.55 -1.79 -25 -35 -20 -70 16 -48 -28
Net Cash From Investing Activities		 -33 -149 -108 -27 -28 -68 -105 -16 -19 -405 -34
Net Cash From Continuing Investing Activities		 -33 -149 -108 -27 -28 -68 -105 -16 -19 -405 -34
Purchase of Property, Plant & Equipment		 -2.18 -4.57 -10 -5.74 -6.64 -6.14 -2.56 -8.88 -8.87 -16 -14
Acquisitions		 -31 -144 -98 -22 -21 -62 -106 -7.61 -9.64 -402 -20
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 2.65 0.75 0.00 14 0.00
Net Cash From Financing Activities		 1.07 -0.73 72 -28 1.25 -1.44 195 -5.13 67 265 -9.94
Net Cash From Continuing Financing Activities		 1.07 -0.73 72 -28 1.25 -1.44 195 -5.13 67 265 -9.94
Repayment of Debt		 0.00 -0.29 -2.74 -31 -121 -16 75 -3.00 -3.00 -313 -10
Repurchase of Common Equity		 0.00 -2.50 - - -1.03 -1.52 -0.89 -1.96 -4.99 -11 -12
Payment of Dividends		 - - - - 0.00 0.00 -0.19 -1.63 -1.63 -1.63 -1.16
Issuance of Debt		 0.00 0.00 75 0.00 118 15 24 0.00 0.00 641 0.00
Issuance of Common Equity		 - - - - 0.00 0.00 70 0.00 81 0.00 0.00
Other Financing Activities, net		 1.07 2.07 0.09 2.69 5.74 0.62 2.07 1.46 -3.50 -50 14
Effect of Exchange Rate Changes		 - - - - - - - 0.00 0.00 -0.47 -0.23
Cash Interest Paid		 4.15 4.08 3.76 6.29 6.09 6.93 9.71 21 31 24 27
Cash Income Taxes Paid		 13 9.54 18 6.40 10 4.98 10 0.29 1.23 19 18

Quarterly Cash Flow Statements for ANI Pharmaceuticals

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 31 28 7.48 12 -95 -0.12 4.94 68 45 23 26
Net Cash From Operating Activities		 32 45 18 17 12 16 35 76 44 30 58
Net Cash From Continuing Operating Activities		 32 45 18 17 12 16 35 76 44 30 58
Net Income / (Loss) Continuing Operations		 9.94 1.16 18 -2.29 -24 -10 16 8.55 27 27 29
Consolidated Net Income / (Loss)		 9.94 1.16 18 -2.29 -24 -10 16 8.55 27 27 29
Depreciation Expense		 15 15 15 15 16 23 23 23 23 23 21
Amortization Expense		 1.00 0.95 0.10 0.10 3.35 11 0.32 0.34 0.34 0.35 0.36
Non-Cash Adjustments To Reconcile Net Income		 4.14 7.57 -21 14 17 28 5.27 31 -1.01 10 -6.48
Changes in Operating Assets and Liabilities, net		 1.88 20 6.24 -9.22 0.08 -35 -9.17 13 -4.52 -30 14
Net Cash From Investing Activities		 -4.55 -4.78 8.93 -4.45 -399 -11 -20 -6.91 -6.16 -1.40 -11
Net Cash From Continuing Investing Activities		 -4.55 -4.78 8.93 -4.45 -399 -11 -20 -6.91 -6.16 -1.40 -11
Purchase of Property, Plant & Equipment		 -1.74 -2.28 -4.58 -4.45 -4.81 -2.39 -2.47 -4.01 -6.10 -1.24 -6.07
Acquisitions		 -2.81 -2.50 0.00 - -394 -8.29 -17 -2.90 -0.06 -0.16 -5.25
Net Cash From Financing Activities		 3.76 -12 -20 -1.45 291 -4.91 -9.91 -1.75 6.35 -4.64 -22
Net Cash From Continuing Financing Activities		 3.76 -12 -20 -1.45 291 -4.91 -9.91 -1.75 6.35 -4.64 -22
Repayment of Debt		 -0.75 -0.75 -0.75 -0.75 -308 -4.01 -2.03 -2.03 -2.03 -4.06 -4.06
Repurchase of Common Equity		 -0.67 -0.23 -8.66 -1.30 -0.68 -0.32 -10 -0.55 -1.04 -0.61 -20
Payment of Dividends		 -0.41 -0.41 -0.41 -0.41 -0.41 -0.41 -0.41 -0.41 -0.34 - 0.00
Other Financing Activities, net		 5.58 -11 -9.91 1.01 -41 -0.18 2.53 1.24 9.76 0.04 2.20
Effect of Exchange Rate Changes		 - - 0.00 - - -0.40 -0.30 0.84 0.58 -1.35 0.16
Cash Interest Paid		 7.97 8.01 7.95 8.21 3.08 5.15 8.90 4.97 8.46 4.61 7.82
Cash Income Taxes Paid		 0.79 0.30 0.85 16 0.01 1.85 0.29 16 0.14 1.06 -6.07

Annual Balance Sheets for ANI Pharmaceuticals

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 285 323 412 431 457 461 772 760 904 1,284 1,440
Total Current Assets		 193 103 132 153 188 170 322 344 520 528 753
Cash & Equivalents		 155 27 31 43 62 7.86 100 48 221 145 286
Restricted Cash		 - - - - - - 0.00 5.01 0.00 0.03 0.04
Short-Term Investments		 - - - - - - - - 0.00 6.31 9.13
Accounts Receivable		 22 46 59 65 72 96 129 165 162 222 281
Inventories, net		 13 26 38 41 48 61 82 105 111 137 143
Prepaid Expenses		 1.45 3.56 2.78 4.52 5.07 5.86 11 12 17 19 34
Plant, Property, & Equipment, net		 7.13 11 20 38 41 41 53 43 45 57 62
Total Noncurrent Assets		 86 209 260 240 229 250 397 373 340 699 625
Goodwill		 1.84 1.84 1.84 3.58 3.58 3.58 28 28 28 60 62
Intangible Assets		 66 176 230 202 180 189 294 252 209 542 480
Noncurrent Deferred & Refundable Income Taxes		 17 26 23 28 38 52 68 81 91 85 69
Other Noncurrent Operating Assets		 - 0.00 0.83 1.47 1.22 0.80 2.21 11 12 12 14
Total Liabilities & Shareholders' Equity		 285 323 412 431 457 461 772 760 904 1,284 1,440
Total Liabilities		 125 153 237 233 244 265 413 422 447 856 900
Total Current Liabilities		 12 32 39 166 62 79 88 99 145 194 278
Short-Term Debt		 - 0.00 3.35 3.26 9.94 13 0.85 0.85 13 9.20 17
Accounts Payable		 2.07 3.39 3.63 8.88 15 11 23 29 37 46 63
Accrued Expenses		 5.85 19 22 19 16 17 19 26 34 55 109
Current Deferred & Payable Income Tax Liabilities		 0.00 2.40 0.00 5.02 0.00 3.91 - 0.00 8.16 7.52 2.24
Current Employee Benefit Liabilities		 1.19 1.63 2.31 3.52 3.74 6.23 8.52 10 24 38 38
Other Current Liabilities		 2.65 5.76 8.27 125 17 27 36 33 30 39 50
Total Noncurrent Liabilities		 113 121 198 68 182 187 325 322 301 661 622
Long-Term Debt		 113 121 198 67 176 172 287 286 285 615 600
Other Noncurrent Operating Liabilities		 0.00 0.63 0.00 0.50 6.51 14 39 36 17 47 22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 160 170 175 197 213 196 334 314 433 404 541
Total Preferred & Common Equity		 160 170 175 197 213 196 334 314 433 404 541
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 160 170 175 197 213 196 334 314 433 404 541
Common Stock		 164 173 179 187 201 214 388 404 514 520 596
Retained Earnings		 -4.35 -2.92 -4.01 11 18 -4.97 -48 -97 -80 -100 -23
Treasury Stock		 - 0.00 -0.26 -0.66 -0.72 -2.25 -3.14 -5.09 -10 -21 -33
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.38 -4.87 -11 -3.06 12 8.86 5.34 1.03
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for ANI Pharmaceuticals

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 739 765 859 890 915 921 1,287 1,292 1,343 1,408 1,422
Total Current Assets		 309 365 459 497 541 555 521 536 603 698 747
Cash & Equivalents		 56 68 162 193 229 240 145 150 218 263 311
Restricted Cash		 - 0.00 0.00 0.00 - - 0.04 0.03 0.04 0.04 0.04
Short-Term Investments		 - - - - 9.66 6.94 8.30 5.39 5.72 8.86 15
Accounts Receivable		 140 175 173 179 172 166 196 220 226 253 255
Inventories, net		 96 104 104 107 114 125 148 137 138 146 143
Prepaid Expenses		 8.75 11 12 11 16 17 24 23 15 28 22
Plant, Property, & Equipment, net		 43 43 44 44 49 52 57 58 59 64 67
Total Noncurrent Assets		 387 357 356 349 325 314 709 698 681 646 608
Goodwill		 28 28 28 28 28 28 60 61 61 62 62
Intangible Assets		 264 239 230 220 196 183 570 538 520 500 467
Noncurrent Deferred & Refundable Income Taxes		 77 81 82 84 88 90 68 88 92 71 67
Other Noncurrent Operating Assets		 12 9.23 16 16 14 13 11 10 8.25 12 12
Total Liabilities & Shareholders' Equity		 739 765 859 890 915 921 1,287 1,292 1,343 1,408 1,422
Total Liabilities		 402 426 425 435 438 440 857 849 881 902 860
Total Current Liabilities		 82 126 123 134 137 140 190 202 237 271 240
Short-Term Debt		 0.85 24 26 25 1.26 1.69 8.44 11 14 15 19
Accounts Payable		 19 33 29 34 49 49 61 53 55 70 70
Accrued Expenses		 20 22 27 28 32 40 54 58 84 102 86
Current Deferred & Payable Income Tax Liabilities		 - - - 0.59 11 0.00 0.00 14 3.29 0.00 5.30
Current Employee Benefit Liabilities		 7.75 13 11 15 9.53 16 30 22 33 33 16
Other Current Liabilities		 34 34 30 31 33 34 37 42 49 50 43
Total Noncurrent Liabilities		 321 300 302 301 301 300 667 647 645 632 620
Long-Term Debt		 286 285 285 285 285 284 618 612 608 605 594
Other Noncurrent Operating Liabilities		 35 14 17 16 16 16 48 36 36 27 26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 312 315 410 430 452 456 406 419 437 506 562
Total Preferred & Common Equity		 312 315 410 430 452 456 406 419 437 506 562
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 312 315 410 430 452 456 406 419 437 506 562
Common Stock		 399 408 495 507 524 532 511 531 542 586 608
Retained Earnings		 -93 -96 -90 -81 -62 -65 -90 -85 -77 -51 6.39
Treasury Stock		 -4.98 -8.64 -9.18 -9.85 -19 -20 -21 -31 -32 -33 -53
Accumulated Other Comprehensive Income / (Loss)		 10 11 14 14 9.41 8.33 5.37 3.61 3.31 2.81 0.48
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for ANI Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 36.36% 68.53% 37.49% 13.99% 2.47% 0.93% 3.67% 46.38% 53.87% 26.20% 43.78%
EBITDA Growth		 88.89% 6.79% 28.91% 20.38% -12.02% -55.72% -81.24% 415.30% 281.11% -28.95% 145.93%
EBIT Growth		 62.36% -38.90% 41.88% 22.64% -53.68% -202.40% -167.33% 21.58% 235.24% -107.37% 3,953.57%
NOPAT Growth		 -22.05% -60.65% -120.48% 1,565.46% 15.52% -135.52% -148.46% 11.33% 279.72% -99.08% 22,123.79%
Net Income Growth		 -46.52% -74.41% -127.35% 1,539.96% -60.67% -470.00% -88.94% -12.42% 139.21% -198.63% 522.94%
EPS Growth		 -49.03% -74.24% -126.47% 1,544.44% -61.54% -476.00% -80.85% 10.29% 127.87% -222.35% 419.23%
Operating Cash Flow Growth		 -21.64% 59.13% 43.49% 70.16% -31.97% -66.54% -78.24% -1,039.28% 481.24% -46.19% 189.34%
Free Cash Flow Firm Growth		 -3.66% -606.37% 35.34% 275.66% -154.07% 39.18% -312.24% 72.16% 246.82% -548.20% 135.22%
Invested Capital Growth		 53.74% 117.06% 31.87% -35.38% 50.68% 11.27% 46.75% 5.74% -6.54% 68.68% -4.25%
Revenue Q/Q Growth		 -3.78% 18.60% 5.41% 5.13% -4.24% 4.66% 1.73% 11.76% 8.33% 10.61% 6.83%
EBITDA Q/Q Growth		 -5.35% -2.26% 13.11% 7.52% -18.71% 22.61% -80.74% 2,362.17% 4.24% -4.38% 23.44%
EBIT Q/Q Growth		 -12.30% -20.04% 27.49% 11.50% -49.41% 23.08% -151.47% 44.89% 11.73% -119.94% 75.78%
NOPAT Q/Q Growth		 -47.49% -36.52% -111.66% 3,324.49% 7.85% 23.80% -152.83% 41.99% 4.07% -95.00% 57.33%
Net Income Q/Q Growth		 -54.11% -50.14% -114.40% 3,461.84% -62.75% 5.05% -92.76% 29.35% 40.34% -161.20% 93.09%
EPS Q/Q Growth		 -55.10% -50.00% -114.29% 6,400.00% -62.96% 4.57% -85.79% 34.13% 66.67% -92.59% 91.91%
Operating Cash Flow Q/Q Growth		 -25.92% 36.73% 10.43% 20.53% -32.95% -40.78% -66.10% 19.97% 70.38% -31.09% 8.50%
Free Cash Flow Firm Q/Q Growth		 -57.65% 1.50% -194.16% 496.53% -149.62% 69.15% -733.51% 75.94% 145.49% -12.98% 20.47%
Invested Capital Q/Q Growth		 -1.12% -3.21% 9.34% -37.04% 52.29% 2.33% 44.94% 1.73% -6.48% -0.30% 0.99%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 83.37% 62.07% 55.31% 63.77% 69.42% 58.19% 53.45% 56.13% 62.71% 100.00% 61.36%
EBITDA Margin		 60.89% 38.59% 36.18% 38.21% 32.81% 14.39% 2.60% 9.17% 22.70% 12.78% 23.62%
Operating Margin		 42.84% 15.61% 16.02% 17.54% 7.92% -7.68% -18.41% -11.15% 9.65% 0.10% 12.58%
EBIT Margin		 42.90% 15.55% 16.05% 17.27% 7.81% -7.92% -20.42% -10.94% 9.62% -0.56% 13.11%
Profit (Net Income) Margin		 20.14% 3.06% -0.61% 7.69% 2.95% -10.82% -19.71% -15.14% 3.86% -3.01% 8.87%
Tax Burden Percent		 70.75% 45.33% -6.58% 77.27% 193.03% 86.85% 76.00% 76.43% 94.50% 83.39% 81.78%
Interest Burden Percent		 66.38% 43.38% 57.60% 57.60% 19.58% 157.25% 127.01% 181.04% 42.45% 644.01% 82.68%
Effective Tax Rate		 29.26% 54.67% 106.58% 22.73% -93.03% 0.00% 0.00% 0.00% 5.50% 0.00% 18.22%
Return on Invested Capital (ROIC)		 23.59% 4.83% -0.62% 9.76% 11.46% -3.20% -6.13% -4.44% 8.02% 0.06% 10.30%
ROIC Less NNEP Spread (ROIC-NNEP)		 38.55% -17.15% 0.00% -2.83% -24.69% -10.99% -14.44% -15.61% -8.49% -6.83% 7.15%
Return on Net Nonoperating Assets (RNNOA)		 -13.34% -2.45% 0.00% -1.43% -8.48% -7.84% -9.24% -9.30% -3.31% -4.24% 5.87%
Return on Equity (ROE)		 10.25% 2.39% -0.62% 8.33% 2.97% -11.04% -15.37% -13.74% 4.72% -4.18% 16.16%
Cash Return on Invested Capital (CROIC)		 -18.77% -69.01% -28.11% 52.74% -28.98% -13.88% -44.02% -10.01% 14.79% -51.07% 14.64%
Operating Return on Assets (OROA)		 12.02% 6.58% 7.72% 8.26% 3.63% -3.60% -7.16% -4.52% 5.62% -0.32% 8.50%
Return on Assets (ROA)		 5.64% 1.29% -0.29% 3.68% 1.37% -4.91% -6.91% -6.25% 2.26% -1.69% 5.75%
Return on Common Equity (ROCE)		 10.25% 2.39% -0.62% 8.33% 2.97% -11.04% -14.68% -12.76% 4.42% -3.95% 15.75%
Return on Equity Simple (ROE_SIMPLE)		 9.60% 2.32% -0.62% 7.85% 2.86% -11.52% -12.76% -15.27% 4.34% -4.59% 0.00%
Net Operating Profit after Tax (NOPAT)		 23 9.10 -1.86 27 32 -11 -28 -25 44 0.41 91
NOPAT Margin		 30.31% 7.08% -1.05% 13.55% 15.28% -5.38% -12.89% -7.81% 9.12% 0.07% 10.28%
Net Nonoperating Expense Percent (NNEP)		 -14.96% 21.98% -0.62% 12.59% 36.15% 7.79% 8.31% 11.17% 16.52% 6.89% 3.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -4.11% 6.07% 0.04% 7.85%
Cost of Revenue to Revenue		 16.63% 37.93% 44.69% 36.23% 30.58% 41.81% 46.55% 43.87% 37.29% 0.00% 38.64%
SG&A Expenses to Revenue		 27.72% 21.64% 17.86% 21.86% 27.04% 31.17% 39.00% 39.21% 33.22% 40.63% 35.97%
R&D to Revenue		 3.77% 2.26% 5.13% 7.63% 9.59% 7.68% 5.26% 7.05% 7.04% 7.26% 5.85%
Operating Expenses to Revenue		 40.53% 46.46% 39.29% 46.23% 61.51% 65.88% 71.86% 67.25% 53.07% 99.90% 48.79%
Earnings before Interest and Taxes (EBIT)		 33 20 28 35 16 -17 -44 -35 47 -3.45 116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 46 50 64 77 68 30 5.63 29 111 79 209
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.24 4.14 4.30 2.71 3.50 1.83 1.76 2.24 2.60 2.88 3.28
Price to Tangible Book Value (P/TBV)		 5.65 0.00 0.00 0.00 25.87 99.44 49.46 20.77 5.76 0.00 0.00
Price to Revenue (P/Rev)		 6.80 5.46 4.25 2.65 3.61 1.72 2.72 2.22 2.31 1.89 2.01
Price to Earnings (P/E)		 33.75 178.61 0.00 34.45 122.36 0.00 0.00 0.00 65.69 0.00 22.98
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.96% 0.56% 0.00% 2.90% 0.82% 0.00% 0.00% 0.00% 1.52% 0.00% 4.35%
Enterprise Value to Invested Capital (EV/IC)		 4.02 3.09 2.71 2.55 2.62 1.46 1.48 1.68 2.30 1.84 2.43
Enterprise Value to Revenue (EV/Rev)		 6.26 6.19 5.21 2.78 4.21 2.57 3.70 3.04 2.52 2.70 2.37
Enterprise Value to EBITDA (EV/EBITDA)		 10.28 16.04 14.40 7.29 12.83 17.89 142.06 33.13 11.12 21.14 10.05
Enterprise Value to EBIT (EV/EBIT)		 14.59 39.79 32.46 16.13 53.90 0.00 0.00 0.00 26.25 0.00 18.09
Enterprise Value to NOPAT (EV/NOPAT)		 20.65 87.44 0.00 20.55 27.53 0.00 0.00 0.00 27.68 4,061.24 23.07
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.67 28.97 23.38 8.37 19.05 35.15 240.67 0.00 10.33 25.93 11.32
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 3.80 0.00 0.00 0.00 0.00 15.02 0.00 16.23
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.71 0.71 1.15 0.36 0.87 0.95 0.80 0.85 0.65 1.46 1.14
Long-Term Debt to Equity		 0.71 0.71 1.13 0.34 0.83 0.88 0.80 0.84 0.62 1.44 1.11
Financial Leverage		 -0.35 0.14 0.74 0.51 0.34 0.71 0.64 0.60 0.39 0.62 0.82
Leverage Ratio		 1.82 1.84 2.13 2.27 2.16 2.25 2.22 2.20 2.09 2.47 2.81
Compound Leverage Factor		 1.21 0.80 1.23 1.30 0.42 3.53 2.82 3.98 0.89 15.90 2.32
Debt to Total Capital		 41.47% 41.56% 53.55% 26.34% 46.61% 48.69% 44.48% 45.84% 39.43% 59.29% 53.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.89% 1.22% 2.49% 3.47% 0.13% 0.14% 1.74% 0.87% 1.51%
Long-Term Debt to Total Capital		 41.47% 41.56% 52.66% 25.13% 44.11% 45.21% 44.35% 45.70% 37.70% 58.42% 51.80%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.85% 3.98% 3.29% 2.36% 0.00%
Common Equity to Total Capital		 58.53% 58.44% 46.45% 73.66% 53.39% 51.31% 51.68% 50.19% 57.28% 38.35% 46.70%
Debt to EBITDA		 2.44 2.43 3.15 0.92 2.74 6.19 51.06 9.88 2.70 7.95 2.96
Net Debt to EBITDA		 -0.89 1.88 2.66 0.36 1.82 5.93 33.24 8.04 0.70 6.02 1.55
Long-Term Debt to EBITDA		 2.44 2.43 3.10 0.87 2.59 5.75 50.91 9.85 2.58 7.83 2.87
Debt to NOPAT		 4.90 13.25 -108.08 2.58 5.89 -16.56 -10.32 -11.60 6.71 1,526.71 6.79
Net Debt to NOPAT		 -1.78 10.25 -91.37 1.01 3.91 -15.86 -6.72 -9.45 1.73 1,156.85 3.55
Long-Term Debt to NOPAT		 4.90 13.25 -106.28 2.46 5.57 -15.38 -10.29 -11.57 6.42 1,504.21 6.60
Altman Z-Score		 3.87 3.61 2.81 2.11 2.79 1.37 1.22 1.47 2.60 1.49 2.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.48% 7.13% 6.24% 5.61% 2.56%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.38 3.22 3.35 0.92 3.04 2.17 3.68 3.46 3.57 2.72 2.71
Quick Ratio		 15.02 2.29 2.29 0.65 2.18 1.32 2.61 2.15 2.63 1.93 2.07
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -130 -84 148 -80 -49 -200 -56 82 -367 129
Operating Cash Flow to CapEx		 790.84% 601.66% 380.16% 1,167.93% 687.73% 248.85% 0.00% -383.99% 1,341.44% 2,351.84% 1,338.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -49.09 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.57 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.21 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.28 0.42 0.48 0.48 0.47 0.45 0.35 0.41 0.58 0.56 0.65
Accounts Receivable Turnover		 3.89 3.79 3.38 3.26 3.02 2.48 1.93 2.15 2.97 3.20 3.51
Inventory Turnover		 1.21 2.47 2.47 1.87 1.42 1.60 1.41 1.48 1.68 0.00 2.44
Fixed Asset Turnover		 12.36 14.19 11.26 6.89 5.25 5.10 4.60 6.60 11.08 12.11 14.80
Accounts Payable Turnover		 5.38 17.88 22.52 11.67 5.38 6.74 5.88 5.31 5.50 0.00 6.31
Days Sales Outstanding (DSO)		 93.80 96.24 108.03 111.93 121.02 147.00 189.41 169.57 122.78 114.01 103.88
Days Inventory Outstanding (DIO)		 300.60 148.04 147.58 195.51 256.22 228.17 258.48 245.97 217.73 0.00 149.64
Days Payable Outstanding (DPO)		 67.87 20.41 16.21 31.27 67.88 54.16 62.09 68.74 66.35 0.00 57.88
Cash Conversion Cycle (CCC)		 326.53 223.87 239.40 276.17 309.37 321.00 385.80 346.80 274.16 114.01 195.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 119 258 340 220 331 369 541 572 534 901 863
Invested Capital Turnover		 0.78 0.68 0.59 0.72 0.75 0.60 0.48 0.57 0.88 0.86 1.00
Increase / (Decrease) in Invested Capital		 42 139 82 -120 111 37 172 31 -37 367 -38
Enterprise Value (EV)		 478 796 921 561 869 537 800 961 1,229 1,660 2,096
Market Capitalization		 519 703 751 534 746 359 588 703 1,127 1,162 1,774
Book Value per Share		 $13.92 $14.64 $15.00 $16.64 $17.60 $15.84 $26.18 $17.96 $21.17 $19.20 $24.07
Tangible Book Value per Share		 $7.99 ($0.69) ($4.88) ($0.67) $2.38 $0.29 $0.93 $1.94 $9.57 ($9.42) ($0.06)
Total Capital		 274 290 376 268 399 381 646 625 756 1,053 1,158
Total Debt		 113 121 202 71 186 186 287 287 298 624 617
Total Long-Term Debt		 113 121 198 67 176 172 287 286 285 615 600
Net Debt		 -41 93 170 28 123 178 187 233 77 473 322
Capital Expenditures (CapEx)		 2.18 4.57 10 5.74 6.64 6.14 -0.09 8.13 8.87 2.72 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 26 44 65 -52 74 97 135 192 166 192 198
Debt-free Net Working Capital (DFNWC)		 181 71 96 -9.42 136 105 235 246 387 343 492
Net Working Capital (NWC)		 181 71 92 -13 126 92 234 245 374 334 475
Net Nonoperating Expense (NNE)		 7.76 5.17 -0.79 12 25 11 15 23 26 19 13
Net Nonoperating Obligations (NNO)		 -41 88 165 23 118 173 182 233 77 473 322
Total Depreciation and Amortization (D&A)		 14 30 36 42 52 47 50 64 64 82 93
Debt-free, Cash-free Net Working Capital to Revenue		 34.25% 33.97% 36.52% -26.01% 35.65% 46.59% 62.36% 60.82% 34.17% 31.25% 22.38%
Debt-free Net Working Capital to Revenue		 236.93% 55.25% 54.13% -4.67% 65.83% 50.37% 108.77% 77.65% 79.59% 55.86% 55.75%
Net Working Capital to Revenue		 236.93% 55.25% 52.24% -6.29% 61.01% 44.01% 108.38% 77.38% 76.90% 54.36% 53.77%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.34 $0.34 ($0.09) $1.31 $0.51 ($1.88) ($3.40) ($3.05) $0.86 ($1.04) $3.50
Adjusted Weighted Average Basic Shares Outstanding		 11.37M 11.45M 11.55M 11.68M 11.84M 11.96M 12.60M 16.26M 18.00M 19.32M 20.05M
Adjusted Diluted Earnings per Share		 $1.32 $0.34 ($0.09) $1.30 $0.50 ($1.88) ($3.40) ($3.05) $0.85 ($1.04) $3.32
Adjusted Weighted Average Diluted Shares Outstanding		 11.56M 11.57M 11.55M 11.77M 12.04M 11.96M 12.60M 16.26M 18.19M 19.32M 21.23M
Adjusted Basic & Diluted Earnings per Share		 $1.34 $0.00 $0.00 $0.00 $0.51 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.46M 11.60M 11.66M 11.86M 12.11M 12.37M 17.27M 17.50M 21.08M 21.77M 22.42M
Normalized Net Operating Profit after Tax (NOPAT)		 23 19 20 27 11 -11 -20 -18 47 1.55 66
Normalized NOPAT Margin		 30.31% 14.57% 11.57% 13.55% 5.57% -5.23% -9.12% -5.72% 9.61% 0.25% 7.52%
Pre Tax Income Margin		 28.48% 6.75% 9.25% 9.95% 1.53% -12.45% -25.94% -19.81% 4.08% -3.62% 10.84%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.83 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.45% -3.39% 8.65% -8.77% 1.48%
Augmented Payout Ratio		 0.00% 63.55% 0.00% 0.00% 16.92% -6.75% -2.54% -7.48% 35.21% -67.94% 17.06%

Quarterly Metrics And Ratios for ANI Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 22,424,968.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 22,424,968.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 57.27% 39.71% 28.70% 18.44% 12.52% 44.75% 43.43% 53.12% 53.58% 29.64% 20.46%
EBITDA Growth		 199.60% 24.48% 75.05% -38.76% -107.64% -15.74% 8.86% 130.65% 2,459.90% 130.34% 34.06%
EBIT Growth		 461.21% 276.43% 203.57% -80.82% -221.16% -309.98% -14.91% 573.83% 277.55% 563.28% 72.71%
NOPAT Growth		 543.26% 543.90% 121.95% -75.48% -192.68% -137.36% 40.79% 211.86% 298.69% 1,090.71% 38.75%
Net Income Growth		 215.58% 127.22% 1,165.25% -136.62% -343.12% -989.70% -13.87% 473.81% 210.14% 367.52% 88.07%
EPS Growth		 181.82% 117.24% 1,266.67% -148.28% -382.22% -1,000.00% -15.85% 357.14% 188.98% 353.33% 85.51%
Operating Cash Flow Growth		 787.91% 1,116.82% -14.73% -15.57% -61.22% -64.55% 91.53% 335.35% 253.17% 91.47% 66.83%
Free Cash Flow Firm Growth		 103.20% 253.37% 410.18% 598.54% -5,726.90% -911.35% -616.24% -585.08% 122.47% 118.55% 124.53%
Invested Capital Growth		 1.66% -6.54% -9.70% -11.00% 58.22% 68.68% 73.77% 65.52% -5.47% -4.25% -6.73%
Revenue Q/Q Growth		 13.11% -0.13% 4.39% 0.44% 7.46% 28.48% 3.44% 7.23% 7.78% 8.45% -3.88%
EBITDA Q/Q Growth		 21.72% -33.05% 95.82% -61.63% -115.18% 838.45% 152.99% -18.69% 55.36% -4.30% 10.90%
EBIT Q/Q Growth		 45.02% -62.63% 347.26% -92.09% -1,015.96% 35.23% 281.24% -37.33% 141.35% -6.84% 22.57%
NOPAT Q/Q Growth		 5.04% -47.07% 77.94% -75.21% -496.96% 78.66% 770.59% -45.09% 152.91% 6.39% -6.08%
Net Income Q/Q Growth		 59.17% -88.38% 1,476.36% -112.56% -956.67% 57.48% 252.60% -45.48% 211.35% 3.28% 7.28%
EPS Q/Q Growth		 55.17% -88.89% 1,540.00% -117.07% -807.14% 64.57% 253.33% -47.83% 213.89% 0.89% 12.28%
Operating Cash Flow Q/Q Growth		 55.96% 39.08% -59.17% -4.68% -28.37% 27.14% 120.62% 116.66% -41.89% -31.07% 92.23%
Free Cash Flow Firm Q/Q Growth		 145.31% 639.61% 55.56% -4.37% -611.40% -6.65% 1.02% 10.14% 123.69% -11.98% 30.91%
Invested Capital Q/Q Growth		 -2.13% -6.48% -1.87% -0.91% 73.99% -0.30% 1.09% -5.62% -0.63% 0.99% -1.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.51% 59.42% 64.23% 58.20% 57.48% 189.17% 62.95% 64.70% 59.01% 59.42% 60.59%
EBITDA Margin		 25.88% 17.35% 32.54% 12.43% -1.76% 10.10% 24.70% 18.73% 27.00% 23.82% 27.49%
Operating Margin		 13.61% 5.11% 14.78% 3.74% -13.83% -2.30% 13.29% 6.57% 15.91% 14.07% 16.38%
EBIT Margin		 13.59% 5.08% 21.78% 1.72% -14.63% -7.37% 12.92% 7.55% 16.91% 14.53% 18.53%
Profit (Net Income) Margin		 7.54% 0.88% 13.25% -1.66% -16.29% -5.39% 7.96% 4.04% 11.68% 11.13% 12.42%
Tax Burden Percent		 86.35% 121.96% 71.87% 100.00% 76.72% 74.67% 78.46% 81.23% 78.75% 87.33% 73.32%
Interest Burden Percent		 64.27% 14.15% 84.63% -96.54% 145.16% 97.92% 78.47% 65.93% 87.73% 87.71% 91.43%
Effective Tax Rate		 13.65% -21.96% 28.14% 0.00% 0.00% 0.00% 21.54% 18.77% 21.25% 12.67% 26.68%
Return on Invested Capital (ROIC)		 9.32% 5.48% 9.95% 2.56% -7.29% -1.38% 9.79% 5.78% 11.78% 12.30% 12.60%
ROIC Less NNEP Spread (ROIC-NNEP)		 6.07% 0.94% 12.44% -3.71% -10.61% -4.00% 7.90% 4.53% 11.31% 11.58% 12.85%
Return on Net Nonoperating Assets (RNNOA)		 2.63% 0.37% 4.40% -0.76% -7.07% -2.48% 4.42% 2.11% 9.93% 9.50% 9.66%
Return on Equity (ROE)		 11.95% 5.85% 14.35% 1.80% -14.36% -3.86% 14.21% 7.89% 21.71% 21.81% 22.25%
Cash Return on Invested Capital (CROIC)		 5.88% 14.79% 18.78% 18.56% -43.98% -51.07% -53.26% -47.81% 12.19% 14.64% 18.13%
Operating Return on Assets (OROA)		 7.50% 2.97% 13.42% 1.04% -7.46% -4.14% 7.89% 4.99% 10.38% 9.42% 12.61%
Return on Assets (ROA)		 4.16% 0.51% 8.16% -1.00% -8.31% -3.03% 4.86% 2.67% 7.17% 7.21% 8.45%
Return on Common Equity (ROCE)		 11.20% 5.48% 13.48% 1.70% -13.56% -3.64% 13.45% 7.47% 21.13% 21.25% 21.70%
Return on Equity Simple (ROE_SIMPLE)		 3.11% 0.00% 7.87% 5.93% -1.75% 0.00% -5.03% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 15 8.20 15 3.62 -14 -3.06 21 11 29 30 29
NOPAT Margin		 11.76% 6.23% 10.62% 2.62% -9.68% -1.61% 10.43% 5.34% 12.53% 12.29% 12.01%
Net Nonoperating Expense Percent (NNEP)		 3.25% 4.55% -2.50% 6.27% 3.32% 2.62% 1.89% 1.25% 0.47% 0.72% -0.26%
Return On Investment Capital (ROIC_SIMPLE)		 - 1.12% - - - -0.30% 1.97% 1.07% 2.53% 2.62% 2.42%
Cost of Revenue to Revenue		 36.49% 40.58% 35.77% 41.80% 42.52% -89.17% 37.05% 35.30% 40.99% 40.58% 39.41%
SG&A Expenses to Revenue		 31.86% 33.77% 34.94% 38.27% 53.31% 36.58% 38.82% 38.69% 33.65% 33.51% 31.02%
R&D to Revenue		 8.44% 7.49% 7.65% 5.29% 6.83% 8.73% 5.36% 7.82% 5.40% 4.96% 4.46%
Operating Expenses to Revenue		 49.90% 54.32% 49.45% 54.46% 71.31% 191.46% 49.66% 58.13% 43.10% 45.34% 44.21%
Earnings before Interest and Taxes (EBIT)		 18 6.69 30 2.37 -22 -14 25 16 39 36 44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 34 23 45 17 -2.61 19 49 40 61 59 65
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.74 2.60 3.22 2.93 3.09 2.88 3.48 3.24 3.93 3.28 3.07
Price to Tangible Book Value (P/TBV)		 6.48 5.76 6.40 5.46 0.00 0.00 0.00 0.00 0.00 0.00 52.80
Price to Revenue (P/Rev)		 2.62 2.31 2.82 2.48 2.26 1.89 2.16 1.89 2.40 2.01 1.87
Price to Earnings (P/E)		 100.22 65.69 42.96 52.60 0.00 0.00 0.00 0.00 50.96 22.98 18.87
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.00% 1.52% 2.33% 1.90% 0.00% 0.00% 0.00% 0.00% 1.96% 4.35% 5.30%
Enterprise Value to Invested Capital (EV/IC)		 2.31 2.30 2.92 2.69 1.94 1.84 2.14 2.14 2.73 2.43 2.37
Enterprise Value to Revenue (EV/Rev)		 2.94 2.52 2.96 2.60 3.16 2.70 2.89 2.46 2.83 2.37 2.18
Enterprise Value to EBITDA (EV/EBITDA)		 12.45 11.12 11.79 11.78 21.35 21.14 23.65 17.51 13.82 10.05 8.93
Enterprise Value to EBIT (EV/EBIT)		 31.50 26.25 22.87 24.59 101.37 0.00 0.00 323.32 35.45 18.09 14.97
Enterprise Value to NOPAT (EV/NOPAT)		 30.94 27.68 32.27 36.67 214.32 4,061.24 430.92 172.76 40.46 23.07 20.47
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.90 10.33 13.21 12.43 18.88 25.93 24.16 13.20 13.69 11.32 9.65
Enterprise Value to Free Cash Flow (EV/FCFF)		 39.61 15.02 14.74 13.67 0.00 0.00 0.00 0.00 21.80 16.23 12.60
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.68 0.65 0.60 0.60 1.45 1.46 1.40 1.35 1.23 1.14 1.09
Long-Term Debt to Equity		 0.63 0.62 0.60 0.59 1.44 1.44 1.38 1.32 1.20 1.11 1.06
Financial Leverage		 0.43 0.39 0.35 0.21 0.67 0.62 0.56 0.46 0.88 0.82 0.75
Leverage Ratio		 2.06 2.09 2.06 1.95 2.46 2.47 2.40 2.40 2.88 2.81 2.70
Compound Leverage Factor		 1.32 0.30 1.74 -1.88 3.57 2.42 1.88 1.58 2.52 2.47 2.47
Debt to Total Capital		 40.52% 39.43% 37.48% 37.31% 59.26% 59.29% 58.42% 57.40% 55.09% 53.30% 52.19%
Short-Term Debt to Total Capital		 3.24% 1.74% 0.17% 0.22% 0.80% 0.87% 1.07% 1.26% 1.36% 1.51% 1.64%
Long-Term Debt to Total Capital		 37.28% 37.70% 37.32% 37.09% 58.46% 58.42% 57.35% 56.14% 53.73% 51.80% 50.55%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 3.25% 3.29% 3.26% 3.24% 2.35% 2.36% 2.33% 2.29% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 56.23% 57.28% 59.26% 59.44% 38.39% 38.35% 39.25% 40.30% 44.91% 46.70% 47.81%
Debt to EBITDA		 2.92 2.70 2.20 2.41 7.63 7.95 7.55 5.93 3.67 2.96 2.73
Net Debt to EBITDA		 1.10 0.70 0.37 0.33 5.76 6.02 5.67 3.80 2.06 1.55 1.28
Long-Term Debt to EBITDA		 2.69 2.58 2.19 2.39 7.53 7.83 7.41 5.80 3.58 2.87 2.64
Debt to NOPAT		 7.26 6.71 6.03 7.50 76.59 1,526.71 137.65 58.51 10.74 6.79 6.24
Net Debt to NOPAT		 2.74 1.73 1.00 1.02 57.85 1,156.85 103.36 37.48 6.04 3.55 2.93
Long-Term Debt to NOPAT		 6.68 6.42 6.01 7.45 75.56 1,504.21 135.13 57.22 10.48 6.60 6.05
Altman Z-Score		 2.56 2.45 3.11 2.86 1.47 1.46 1.84 1.80 2.31 2.25 2.39
Noncontrolling Interest Sharing Ratio		 6.28% 6.24% 6.09% 5.43% 5.61% 5.61% 5.40% 5.27% 2.65% 2.56% 2.47%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.70 3.57 3.95 3.97 2.74 2.72 2.66 2.54 2.58 2.71 3.12
Quick Ratio		 2.77 2.63 3.00 2.95 1.84 1.93 1.86 1.90 1.94 2.07 2.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 6.17 46 71 68 -347 -370 -366 -329 78 69 90
Operating Cash Flow to CapEx		 1,849.86% 1,963.14% 0.00% 391.41% 259.23% 662.49% 1,414.35% 1,888.69% 721.86% 2,441.08% 961.06%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -46.47 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 1.67 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 1.03 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.55 0.58 0.62 0.61 0.51 0.56 0.61 0.66 0.61 0.65 0.68
Accounts Receivable Turnover		 2.82 2.97 2.98 3.18 2.96 3.20 3.43 3.82 3.68 3.51 3.88
Inventory Turnover		 1.62 1.68 1.77 1.81 1.75 0.00 0.19 0.31 0.48 2.44 2.58
Fixed Asset Turnover		 10.33 11.08 11.27 11.23 11.01 12.11 12.63 13.48 13.75 14.80 14.74
Accounts Payable Turnover		 6.20 5.50 4.70 5.40 4.70 0.00 0.47 0.79 1.09 6.31 5.90
Days Sales Outstanding (DSO)		 129.66 122.78 122.43 114.80 123.28 114.01 106.34 95.66 99.09 103.88 94.00
Days Inventory Outstanding (DIO)		 224.75 217.73 205.70 201.24 208.06 0.00 1,920.11 1,179.91 755.85 149.64 141.66
Days Payable Outstanding (DPO)		 58.90 66.35 77.66 67.60 77.60 0.00 783.25 461.88 335.39 57.88 61.91
Cash Conversion Cycle (CCC)		 295.50 274.16 250.46 248.43 253.74 114.01 1,243.19 813.69 519.55 195.64 173.75
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 571 534 524 520 904 901 911 860 855 863 850
Invested Capital Turnover		 0.79 0.88 0.94 0.98 0.75 0.86 0.94 1.08 0.94 1.00 1.05
Increase / (Decrease) in Invested Capital		 9.33 -37 -56 -64 333 367 387 340 -49 -38 -61
Enterprise Value (EV)		 1,320 1,229 1,530 1,399 1,753 1,660 1,950 1,837 2,337 2,096 2,012
Market Capitalization		 1,178 1,127 1,457 1,336 1,255 1,162 1,458 1,413 1,988 1,774 1,724
Book Value per Share		 $21.18 $21.17 $21.44 $21.73 $19.29 $19.20 $19.23 $20.16 $23.31 $24.07 $25.07
Tangible Book Value per Share		 $8.96 $9.57 $10.80 $11.66 ($10.66) ($9.42) ($8.29) ($6.65) ($2.60) ($0.06) $1.46
Total Capital		 765 756 763 767 1,057 1,053 1,067 1,084 1,126 1,158 1,176
Total Debt		 310 298 286 286 627 624 623 622 620 617 614
Total Long-Term Debt		 285 285 285 284 618 615 612 608 605 600 594
Net Debt		 117 77 48 39 473 473 468 398 349 322 288
Capital Expenditures (CapEx)		 1.74 2.28 -8.93 4.45 4.81 2.39 2.47 4.01 6.10 1.24 6.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 195 166 167 170 186 192 191 156 172 198 201
Debt-free Net Working Capital (DFNWC)		 388 387 405 417 340 343 346 379 443 492 527
Net Working Capital (NWC)		 363 374 404 415 331 334 334 366 428 475 508
Net Nonoperating Expense (NNE)		 5.56 7.05 -3.61 5.91 9.80 7.21 4.87 2.73 1.92 2.87 -0.98
Net Nonoperating Obligations (NNO)		 117 77 48 39 473 473 468 398 349 322 288
Total Depreciation and Amortization (D&A)		 16 16 15 15 19 33 23 24 23 23 21
Debt-free, Cash-free Net Working Capital to Revenue		 43.30% 34.17% 32.21% 31.56% 33.57% 31.25% 28.29% 20.86% 20.76% 22.38% 21.74%
Debt-free Net Working Capital to Revenue		 86.26% 79.59% 78.25% 77.40% 61.17% 55.86% 51.31% 50.78% 53.59% 55.75% 57.04%
Net Working Capital to Revenue		 80.75% 76.90% 78.01% 77.09% 59.66% 54.36% 49.62% 48.94% 51.74% 53.77% 54.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.46 $0.04 $0.84 ($0.14) ($1.27) ($0.47) $0.70 $0.37 $1.19 $1.24 $1.31
Adjusted Weighted Average Basic Shares Outstanding		 18.88M 18.00M 19.10M 19.32M 19.40M 19.32M 19.61M 19.83M 20.07M 20.05M 20.91M
Adjusted Diluted Earnings per Share		 $0.45 $0.05 $0.82 ($0.14) ($1.27) ($0.45) $0.69 $0.36 $1.13 $1.14 $1.28
Adjusted Weighted Average Diluted Shares Outstanding		 19.13M 18.19M 19.42M 19.32M 19.40M 19.32M 20.05M 20.31M 21.09M 21.23M 21.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 20.44M 21.08M 20.97M 21.04M 21.03M 21.77M 21.66M 21.70M 22.47M 22.42M 22.75M
Normalized Net Operating Profit after Tax (NOPAT)		 13 6.10 11 3.87 -14 -4.39 11 12 18 25 28
Normalized NOPAT Margin		 10.08% 4.63% 7.87% 2.80% -9.29% -2.30% 5.61% 5.83% 7.89% 10.30% 11.95%
Pre Tax Income Margin		 8.73% 0.72% 18.43% -1.66% -21.23% -7.22% 10.14% 4.98% 14.84% 12.74% 16.94%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -2.91 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -1.92 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -3.55 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -2.57 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 12.15% 8.65% 4.57% 6.02% -22.92% -8.77% -7.72% -15.91% 3.85% 1.48% 0.82%
Augmented Payout Ratio		 48.58% 35.21% 32.98% 46.22% -176.24% -67.94% -66.16% -129.03% 33.22% 17.06% 24.65%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways for ANI Pharmaceuticals (ANIP) based on quarterly results from the last four years. The bullets highlight trends in revenue, profitability, cash flow, liquidity, and leverage that could matter to retail investors.

  • Strong revenue growth with stable margins. Total revenue rose to 247,060,000 in Q4 2025 from 190,574,000 in Q4 2024, while gross margin remained around 59–60% (146,791,000 gross profit on 247,060,000 revenue in Q4 2025).
  • Net income improved to positive levels in 2025. Net income attributable to common shareholders reached 27,490,000 in Q4 2025 (26,273,000 in Q3 2025), signaling a material profitability upturn vs prior years.
  • Robust quarterly operating cash flow and solid cash conversion. Net cash from continuing operating activities was 30,367,000 in Q4 2025, contributing to a positive net change in cash of 22,975,000 for the quarter.
  • Free cash flow remains healthy. After roughly 1,244,000 of capital expenditures in Q4 2025, free cash flow was about 29,100,000 (roughly operating cash flow minus capex).
  • Strong liquidity and an solid balance sheet base. Cash and cash equivalents were 262,610,000 at Q3 2025, with total assets around 1.408B and total equity about 506M, indicating solid liquidity and a durable capital base.
  • Solid earnings per share in latest quarter. Q4 2025 basic EPS was 1.24 and diluted EPS was 1.14, supported by roughly 20.0–21.0 million weighted shares outstanding.
  • Intangible assets form a large part of the asset base. Intangible assets were about 499.8M as of late 2025, with depreciation expense of 22.613M in Q4 2025, reflecting ongoing IP investments and amortization cash outflows.
  • Working capital movements are normal for pharma manufacturing. Changes in operating assets and liabilities in Q4 2025 net to about -30.118M, typical for a business with inventories and receivables fluctuating with launches and timing of shipments.
  • Leverage remains a key risk. Long-term debt around 605–608M and total liabilities near 902M (as of mid-2025) keep the company highly levered and sensitive to interest costs or financing conditions.
  • Notable one-time charges in some quarters. Q4 2025 included Other Special Charges / (Income) of about -5.64M, which reduced operating income despite strong revenue and net income in that quarter.
05/30/26 05:42 AM ETAI Generated. May Contain Errors.

ANI Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ANI Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ANI Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $78.34 million in 2025, rising from $15.38 million in 2015. The previous period was -$18.52 million in 2024. View ANI Pharmaceuticals' forecast to see where analysts expect ANI Pharmaceuticals to go next.

ANI Pharmaceuticals' total operating income in 2025 was $111.09 million, based on the following breakdown:
  • Total Gross Profit: $542.06 million
  • Total Operating Expenses: $430.96 million

Over the last 10 years, ANI Pharmaceuticals' total revenue changed from $76.32 million in 2015 to $883.37 million in 2025, a change of 1,057.4%.

ANI Pharmaceuticals' total liabilities were at $899.65 million at the end of 2025, a 5.1% increase from 2024, and a 618.7% increase since 2015.

In the past 10 years, ANI Pharmaceuticals' cash and equivalents has ranged from $7.86 million in 2020 to $285.59 million in 2025, and is currently $285.59 million as of their latest financial filing in 2025.

Over the last 10 years, ANI Pharmaceuticals' book value per share changed from 13.92 in 2015 to 24.07 in 2025, a change of 72.9%.


Related Companies

Financial statements for NASDAQ:ANIP last updated on 5/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
This Tech Could Be Bigger Than Apple, Amazon, and Microsoft Combined
A breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...
Altimetry | Sponsoredtc pixel
One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...
Behind the Markets | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel